Montréal, Monday, January, 21, 2019 – It was with profound sadness that Génome Québec learned of the passing of eminent researcher and physician, Dr. Fernand Labrie.
Throughout his career, Dr. Labrie built a solid reputation among leading medical research scientists. He was behind many discoveries in endocrinology in areas including prostate cancer and hormone therapy for breast cancer. Equally capable as a businessman, in 2006, he founded Endoceutics, a company dedicated to the development and commercialization of therapies in support of women’s health.
“Fernand Labrie was a research pioneer in molecular endocrinology and his contribution will mark the history of Québec. Always ahead of his time, he was among the first researchers funded by Génome Québec for a major project cataloguing the genomic profiles of steroid action. On behalf of the Génome Québec Board of Directors and staff, I would like to extend my deepest sympathies to his family and friends,” stated Daniel Coderre, Génome Québec President and CEO.